Key facts
- This page summarizes John Maraganore's Form 4 filing for ALNYLAM PHARMACEUTICALS, INC. (ALNY).
- 4 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 23 Dec 2021, 16:00.
John Maraganore - 21 Dec 2021 Form 4 Insider Report for ALNYLAM PHARMACEUTICALS, INC. (ALNY)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- ALNY
- Reported as of
- 21 Dec 2021
- Net transaction value
- -$1,254,077
- SEC form
- 4
- Accepted by SEC
- 23 Dec 2021, 16:00:40 UTC
- Prior SEC filing
- 14 Dec 2021
- Next SEC filing
- 19 Jan 2022
- Source filing
- View source filing
- Reporting owner signature
- By: /s/ Mary Beth DeLena, Attorney-in-Fact For: John M. Maraganore
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
John Maraganore filed Form 4 for ALNYLAM PHARMACEUTICALS, INC. (ALNY) on 23 Dec 2021.
Change
- Previous filing in this sequence was filed on 14 Dec 2021.
- Current net transaction value: -$1,254,077.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ALNY
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +14,167
- Change %
- +6.4%
- Price
- $0.000000
- Shares after
- 234,299
- Date
- 21 Dec 2021
- Ownership
- Direct
- Footnotes
- F1
ALNY
transaction
Common Stock
Tax liability
- Transaction value
- $1,194,356
- Shares
- -6,315
- Change %
- -2.7%
- Price
- $189.13
- Shares after
- 227,984
- Date
- 22 Dec 2021
- Ownership
- Direct
- Footnotes
- F2
ALNY
transaction
Common Stock
Tax liability
- Transaction value
- $381
- Shares
- -2
- Change %
- -0%
- Price
- $190.50
- Shares after
- 227,982
- Date
- 22 Dec 2021
- Ownership
- Direct
- Footnotes
- F2
ALNY
transaction
Common Stock
Tax liability
- Transaction value
- $59,340
- Shares
- -319
- Change %
- -0.14%
- Price
- $186.02
- Shares after
- 227,663
- Date
- 22 Dec 2021
- Ownership
- Direct
- Footnotes
- F2
ALNY
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 3,133
- Date
- 21 Dec 2021
- Ownership
- by Managed Account
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
On February 28, 2019, the reporting person was granted performance-based restricted stock units (PSU) in connection with the 2018 year-end compensation review. One third of the PSU award vests upon the achievement of each of three specific clinical development, regulatory or commercial events. The People, Culture and Compensation Committee of the Board determined that the final performance criterion was met and the final one-third of the PSU award vested as of December 21, 2021.
Footnote F2
Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event.
Footnote F3
Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.